NYXH Earnings Prediction
The chart below shows how NYXH performed 10 days before and after its earnings report, based on data from the past quarters. Typically, NYXH sees a +1.18% change in stock price 10 days leading up to the earnings, and a -2.55% change 10 days following the report. On the earnings day itself, the stock moves by +0.96%. This data can give you a slight idea of what to expect for the next quarter's release.
NYXH Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
1.26M
-30.76%
-0.24%
Gross Margin
73.48%
22.06%
18.65%
Operating Margin
-1449.80%
144.02%
22.53%
Net Margin
-1357.80%
127.36%
0.77%
EPS
-0.46
-21.05%
-8.00%
No Data Available
NYXH Earnings Analysis
Nyxoah SA Corporation (NYXH.O) Earnings Conference Call
Positive
Transformative Year Overview: 2024 was a transformative year for Nyxoah with tremendous progress made throughout the year.
Market Launch Timeline: Genio is expected to be brought to market in the U.S. by the end of March 2025.
AHI and ODI Responder Rates: The DREAM study demonstrated a strong AHI responder rate of 63.5% and an ODI responder rate of 71.3%, with an overall median AHI reduction of 70.8%.
Unique Therapy Efficacy: Genio is the only therapy with clinical evidence proving its efficacy irrespective of a patient’s sleeping position, making it a critical differentiator.
AHI Score Improvement: 82% of all DREAM subjects achieved AHI scores dropping below 15, potentially extending patient lives.
Safety Profile Assessment: Genio demonstrated a favorable safety profile with an 8.7% severe adverse event rate.
Team Development for Market Strategy: The company has built a world-class team in support of the U.S. go-to-market strategy and commercial readiness plan.
Physician Training on Genio Technology: 75 physicians have been trained on the Genio technology and are familiar with its unique features and patient outcomes.
Sequential Revenue Growth: The company recorded a 46% sequential growth in revenue over Q3 2024, with €1.9 million in revenue for Q4 2024, excluding deferred revenue.
Revenue Increase Overview: The full year revenue was €5.1 million, an 18% increase over 2023.
Market Growth Potential: Genio was launched in the U.K. and is covered under the NHS Specialized Service Device program, indicating strong potential for growth in that market.
Milestone Implant Success: The first commercial implant of Genio was successfully performed in the UAE, marking a significant milestone in the Middle East.
Strong Cash Position: The company has a strong cash position of €85.6 million as of December 31, 2024, reflecting disciplined cash management as they prepare for U.S. commercialization.
Negative
Operating Loss Increase: Total operating loss for Q4 2024 was €18.3 million, an increase from €10.8 million in Q4 2023, indicating rising costs and financial strain.
Q4 Revenue Shortfall: Revenue recognized in Q4 2024 was only €1.3 million, significantly lower than expected, and the company recorded deferred revenue of €600,000, which may indicate future revenue uncertainty.
Cash Burn Concerns: Despite a strong cash position of €85.6 million, the increase in cash burn due to accelerated R&D spending and commercial investments raises concerns about sustainability.
FDA Approval Dependency: The company is heavily reliant on FDA approval for its U.S. market entry, and any delays or issues could significantly impact future growth and revenue.
Market Penetration Strategy: The need for a two-pronged strategy to penetrate the U.S. market suggests challenges in gaining immediate acceptance and market share against established competitors.
NYXH FAQs
How does NYXH typically perform around its earnings report dates?
Is Nyxoah SA (NYXH) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
NYXH Earning Call Sentiment
Nyxoah S.A. (NASDAQ:NYXH) Q4 2024 Earnings Call Transcript
NYXH.O
-5.39%Positive
The earnings call presents a mixed outlook. Despite positive developments like FDA approval anticipation and strategic U.S. market entry, financial challenges persist, such as increased operating losses and deferred revenue. The Q&A section highlighted uncertainties in reimbursement and payer engagement, although management's confidence in FDA approval and product differentiation is reassuring. Given these factors, the stock price reaction is expected to be neutral, with no significant catalysts to drive a strong move in either direction.
